Company: EUDAW
Filing Date: 2025-09-24
Form Type: 20-F/A
Source: 0001493152-25-014808
Chunk: 32

Company: EUDA Health Holdings Ltd
Filing Date: 2025-09-24
Form: 20-F/A
Chunk 32
---
 | $    |      (0.37 | ) |     | $    |       (2.07 | ) |

The Company calculates basic and diluted earnings/ (loss) per share for discontinued operations as follows:

| Numerator                                                        |     | For the Years Ended December 31 
 2024                            |            |     | 2023 |            |   |     | 2022 |            |
|:-----------------------------------------------------------------|:----|:--------------------------------|-----------:|:----|:-----|-----------:|:--|:----|:-----|-----------:|
| Net income/(loss) attributable to common shareholders, basic     |     | $                               |  2,246,340 |     | $    | (1,601,323 | ) |     | $    |     58,659 |
| Denominator                                                      |     |                                 |            |     |      |            |   |     |      |            |
| Weighted average number of shares outstanding, basic and diluted |     |                                 | 32,459,921 |     |      | 22,900,631 |   |     |      | 12,029,656 |
| Earnings/ (loss) per share, basic and diluted                    |     | $                               |       0.07 |     | $    |      (0.07 | ) |     | $    |       0.00 |

As of December 31, 2024, the Company had dilutive securities from the outstanding convertible notes and warrants convertible into 36,517and 4,458,625of the Company’s ordinary shares, respectively, that were not included in the computation of dilutive loss per share because the inclusion of such convertible notes and warrants would be anti-dilutive.

As of December 31, 2023, the Company had dilutive securities from the outstanding convertible notes and warrants convertible into 422,625and 4,458,625of the Company’s ordinary shares, respectively, that were not included in the computation of dilutive loss per share because the inclusion of such convertible notes and warrants would be anti-dilutive.

As of December 31, 2022, the Company had dilutive securities from the outstanding convertible notes and warrants convertible into 1,411,725and 4,458,625of the Company’s ordinary shares, respectively, that were not included in the computation of dilutive loss per share because the inclusion of such convertible notes and warrants would